Relay Therapeutics, Inc. (RLAY)

NASDAQ: RLAY · IEX Real-Time Price · USD
7.31
-0.52 (-6.58%)
Jun 14, 2024, 4:00 PM EDT - Market closed
-6.58%
Market Cap 970.34M
Revenue (ttm) 35.33M
Net Income (ttm) -329.12M
Shares Out 132.74M
EPS (ttm) -2.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,554,315
Open 7.70
Previous Close 7.83
Day's Range 7.09 - 7.76
52-Week Range 5.70 - 13.32
Beta 1.66
Analysts Strong Buy
Price Target 22.80 (+211.9%)
Earnings Date Aug 6, 2024

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 2020
Employees 323
Stock Exchange NASDAQ
Ticker Symbol RLAY
Full Company Profile

Financial Performance

In 2023, RLAY's revenue was $25.55 million, an increase of 1749.82% compared to the previous year's $1.38 million. Losses were -$341.97 million, 17.7% more than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for RLAY stock is "Strong Buy." The 12-month stock price forecast is $22.8, which is an increase of 211.90% from the latest price.

Price Target
$22.8
(211.90% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Relay Therapeutics Discloses Three New Programs at New Program & Platform Event

3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected t...

8 days ago - GlobeNewsWire

Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608

Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024 Initial triple...

9 days ago - GlobeNewsWire

Relay Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edg...

24 days ago - GlobeNewsWire

Relay Therapeutics to Host New Program and Platform Event on June 6, 2024

CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edg...

4 weeks ago - GlobeNewsWire

Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edg...

6 weeks ago - GlobeNewsWire

Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024

CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e...

7 weeks ago - GlobeNewsWire

Relay Therapeutics to Participate in Three Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

3 months ago - GlobeNewsWire

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort & initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg Initiated RLY-2608 + fulvestrant + ribocicl...

4 months ago - GlobeNewsWire

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024

CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

4 months ago - GlobeNewsWire

Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

4 months ago - GlobeNewsWire

Relay Therapeutics Announces $30 Million Private Placement Financing

CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

5 months ago - GlobeNewsWire

Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

5 months ago - GlobeNewsWire

Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in a fireside chat at the Stifel 2023 Healthcare Conference...

7 months ago - GlobeNewsWire

Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights

Reported initial RLY-4008 (lirafugratinib) data demonstrating durable responses across multiple FGFR2-altered solid tumors Announced plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet combinati...

8 months ago - GlobeNewsWire

Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors

35% ORR in patients with FGFR2 fusions (excluding CCA) & 40% ORR in patients with FGFR2-altered HR+/HER2- breast cancer RLY-4008 commercialization plans to focus on broader tumor agnostic opportunitie...

8 months ago - GlobeNewsWire

Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e...

9 months ago - GlobeNewsWire

Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights

Initiated dose expansion cohort for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer

11 months ago - GlobeNewsWire

Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023

CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

11 months ago - GlobeNewsWire

Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008

Data from FGFRi-naïve FGFR2-fusion CCA patients represent subset of September 2022 presentation and remain consistent with previously reported results Data from FGFRi-naïve FGFR2-fusion CCA patients r...

1 year ago - GlobeNewsWire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in two upcoming fireside chats:

1 year ago - GlobeNewsWire

Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights

Presented initial clinical data for RLY-2608 at American Association for Cancer Research (AACR) Annual Meeting 2023

1 year ago - GlobeNewsWire

Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e...

1 year ago - GlobeNewsWire

Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations

Multiple doses achieved sustained target exposure of ~80%+ mutant PI3Kα inhibition No Grade 3 hyperglycemia, rash or diarrhea observed at target exposures Favorable initial safety profile at target ex...

1 year ago - GlobeNewsWire

Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR

Relay Therapeutics to host conference call following AACR presentation Relay Therapeutics to host conference call following AACR presentation

1 year ago - GlobeNewsWire

Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR treatment-naïve, FGFR2-fusion cholangiocarcinoma patients & announced antic...

1 year ago - GlobeNewsWire